FilingReader Intelligence

Fosun Pharma subsidiary gets US approval for cancer drug trial

August 7, 2025 at 10:20 AM UTC•By FilingReader AI

Shanghai Fosun Pharmaceutical Group's subsidiary Shanghai Henlius Biotech secured US FDA approval for its PD-L1 antibody-drug conjugate HLX43 to begin Phase I clinical trials for thymic carcinoma.

The drug is already in Phase II trials across China, the US, Japan and Australia for non-small cell lung cancer. Cumulative R&D investment reached approximately 182m yuan as of June 2025.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Fosun Pharma's Announcement on Controlled Subsidiary's Drug Clinical Trial Approval from the U.S. FDAAugust 7, 2025 at 08:00 AM UTC

Shanghai Fosun Pharmaceutical Group

SSE:600196•Shanghai Stock Exchange

PharmaceuticalsShanghai Blue Chip

RSS feed for Shanghai Fosun Pharmaceutical Group

News Alerts

Get instant email alerts when Shanghai Fosun Pharmaceutical Group publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →